Georges Awah, MD
Internal Medicine · Washington, DCNPI 1255402418
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 272 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,285 and has fallen 77.3% since, to $292 in 2025. Among internal medicine clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 272 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Boehringer Ingelheim$545
- Novartis$528
- GSK$511
- Merck$460
- Gilead$428
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,582100%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $1,042 |
| Boehringer Ingelheim | 22 | $545 |
| Novartis | 27 | $528 |
| GSK | 26 | $511 |
| Merck | 24 | $460 |
| Gilead | 19 | $428 |
| Lilly USA, LLC | 20 | $416 |
| Pfizer | 17 | $379 |
| Novo Nordisk | 18 | $333 |
| Amgen | 8 | $166 |
| Bayer | 7 | $144 |
| Exact Sciences | 4 | $115 |
| Sanofi-aventis U.S. LLC | 4 | $92 |
| Johnson & Johnson | 5 | $88 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| Abbott | 2 | $46 |
| Mylan Specialty L.p. | 2 | $37 |
| Actelion Pharmaceuticals US, Inc. | 1 | $36 |
| Corcept Therapeutics | 1 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Boston Scientific | 1 | $27 |
| Dexcom, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$5,606 in reported general payments places this provider in the 90th percentile of 645 internal medicine providers in District of Columbia.
See all internal medicine providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $40,474 |
| EliquisApixaban | 30 | $32,207 |
| JardianceEmpagliflozin | 27 | $31,245 |
| OzempicSemaglutide | 22 | $26,534 |
| XareltoRivaroxaban | 23 | $24,894 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 37 | $18,199 |
| JanuviaSitagliptin Phosphate | 15 | $18,135 |
| FarxigaDapagliflozin Propanediol | 12 | $16,805 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $13,003 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $8,940 |
| Atorvastatin Calcium | 456 | $4,677 |
| Clonidine | 18 | $4,276 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $3,322 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 77 | $3,180 |
| Ranolazine ErRanolazine | 20 | $3,113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $545 | $49,44464 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $511 | $49,41460 claims |
| PfizerEliquis | $379 | $32,20730 claims |
| MerckJanuvia, Janumet | $460 | $31,13834 claims |
| Novo NordiskOzempic | $333 | $26,53422 claims |
| Johnson & JohnsonXarelto | $88 | $24,89423 claims |
| AstraZenecaFarxiga, Symbicort | $1,042 | $20,12826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 645 internal medicine providers in District of Columbia.
Other internal medicine in Washington
- Andrea SingerWashington$850K
- Kathryn SowerwineWashington$831K
- Douglas WardWashington$233K
- Geoffrey GibneyWashington$185K
- Kevin GriffithsWashington$180K
- Bruce RashbaumWashington$86K
- Jessica Wang-MemoliWashington$56K
- Dana McGintyWashington$47K
- Geeta NayyarWashington$46K
- Marie BorumWashington$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.